ACTDrug®
101-gene NGS panel with 7-day turnaround for newly diagnosed advanced cancer patients
Software · OtherCompany source
Company profile
About ACT Genomics
AI-powered genomic analysis platform for precision medicine and personalized treatment recommendations.
Company description ACT Genomics official website
Primary marketPrecision Medicine & Genomics
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at ACT Genomics?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Advanced or metastatic cancer
- All solid cancers
- Breast cancer
- Liver cancer
- Ovarian cancer
- Thyroid cancer
Who it serves
- Biopharma companies
- Clinics
- Hospitals
- Patients
- Physicians
- Research institutes
Deployment & integration
Other deployment with recorded integration context.
Geographic context
MarketsAsia-Pacific region · China · Hong Kong · Japan · Singapore · Taiwan · Thailand
Company sourceOfficial website
Company milestones
Platform expansion
FDA 510(k) clearance for ACTOnco® (January 2023). Majority stake acquired by Prenetics Global Limited (December 2022). ISO/IEC 27701:2019 certification (February 2024). ACTDrug® upgraded to 101-gene panel with 7-day turnaround (April 2026). ACTMonitor® Breast expanded to 10-gene panel (February 2026). Delta Electronics board approved proposal to acquire shareholdings (June 2025).
Partnerships
Recorded partners
- AIA Hong Kong
- Canon Medical System Corporation (ACTmed joint venture, 2018)
- Cerba Research (CerbACT Asia joint venture, 2021)
- Delta Group (parent company)
- LSI Medience (Japan, 2026)
- mProbe (proteomics partnership, 2024-2025)
- Nan Shan Life Insurance
- Oncoshot (Singapore)
- Prenetics Global Limited (NASDAQ: PRE, majority stake acquired December 2022)
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
ACTMonitor®
Genomic profiling for monitoring cancer mutations and recurrence
Software · OtherCompany source
ACTMonitor® Breast
10-gene panel for breast cancer monitoring with AKT1 and PTEN biomarkers
Software · OtherCompany source
ACTOnco® IVD
First US FDA 510(k) cleared NGS product in Asia for comprehensive genomic profiling
Software · OtherCompany source
ACTOnco®+
Comprehensive genomic profiling panel for personalized cancer treatment
Software · OtherCompany source
OncoOmicsDX
Integrated proteomics solution for comprehensive cancer care insights
Platform · OtherCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Increased CCR5 expression in lymphoma cells and M2 macrophages is associated with poor prognosis in primary intestinal diffuse large B-cell lymphoma.The journal of pathology. Clinical research · Sep 1, 2026
Oncogenic PIK3CA mutation enhances tumor immunogenicity through the IRF1-NLRC5-MHC-I axis in urothelial carcinoma.Journal for immunotherapy of cancer · Jul 7, 2026
Genomic landscape and comparative analysis of tissue and liquid-based NGS in Taiwanese anaplastic thyroid carcinoma.NPJ precision oncology · Jan 14, 2025
DNA Methylation Biomarker Discovery for Colorectal Cancer Diagnosis Assistance Through Integrated Analysis.Cancer informatics · Jan 1, 2025
Analysis of mutation profiles in extranodal NK/T-cell lymphoma: clinical and prognostic correlations.Annals of hematology · Aug 1, 2024
Study of sex-biased differences in genomic profiles in East Asian hepatocellular carcinoma.Discover oncology · Jul 9, 2024
Clinical validation
Clinical-trial records
Nivolumab Adding on Gemcitabine/S-1 in Metastatic Pancreatic CancerNCT04377048 · Sponsor · UNKNOWN
Analysis of Tumor Mutations and Tumor Microenvironment Using Archival Paraffin-embedded Tumor SpecimensNCT03719222 · Sponsor · UNKNOWN
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Treatment matching
Matching cancer patients with specific treatments and clinical trials through genomic profiling
Cancer recurrence monitoring
Semi-annual monitoring of tumor mutations through ACTMonitor profiling
Catherine (Thyroid Cancer Patient)
20-year thyroid cancer journey with lung metastasis requiring personalized treatment through genetic testing
Tumor brought under control with reduced side effects after tissue-based genetic testing identified specific mutation and matched targeted drug
Nan Shan Life Insurance
Partnership to promote high-quality cancer precision medicine services in Taiwan
AIA Hong Kong
Collaboration to promote precision cancer medicine to insurance customers
Dr. Andrew Tay (Liver Cancer Survivor)
Liver tumor monitoring and recurrence detection through semi-annual genomic profiling
Three rounds of ACTMonitor profiling successfully monitored mutations and assisted in treatment selection for disease management
Ms. Chang (Ovarian Cancer Patient)
18-year ovarian cancer battle with metastasis after multiple rounds of chemotherapy and surgery
Genomic profiling led to treatment recommendation that had not previously been considered when cancer metastasized
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
06 · Company updates
Updates from ACT Genomics
Recent articles published on ACT Genomics's official website.
ACT Genomics and mProbe Announces Strategic Integration of Proteomics to Elevate Precision Medicine in Asia
Read on ACT GenomicsACT Genomics and LSI Medience Sign MOU to form a Strategic Partnership and Collaborate in the Japanese Market
Read on ACT GenomicsACT Genomics and mProbe Announce Strategic Partnership to Advance Precision Medicine in Asia
Read on ACT Genomics07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Precision Medicine & Genomics
Companies using AI to analyze genomic, proteomic, metabolomic, or multi-omics data to provide personalized treatment recommendations, identify genetic risks, or develop targeted therapies. Includes genomic sequencing platforms with AI analysis, preventive medicine based on genetic risk assessment, and longevity care based on molecular and genetic data.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.